Loading stock data…
LFVN
$5.27+0.12 (+2.33%)
Pre-Market$5.27+0.00 (+0.00%)· Last close May 13
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LifeVantage Corporation in the Consumer Defensive sector is trading at $5.27. Wall Street consensus targets $8.00 (2 analysts), implying a +51.8% move over the next 12 months. The stock is currently near its 52-week low of $3.90, remaining 28.3% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +51.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$5.27
Potential Upside
248.1%
Whystock Fair Value$18.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internati...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$62.74M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
8.17
Beta
Defensive asset. Lower volatility than the S&P 500.
0.39
Div Yield
Strong income play. Yield provides a meaningful total return floor.
367.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
29.72%
Volume
Today's trading volume
170,622
Recent News
Lake Street Capital Markets Downgrades LifeVantage Corporation (LFVN) After Weak Q3 Results
LifeVantage Corporation (NASDAQ:LFVN) is included among the 12 Best Micro-Cap Dividend Stocks to Buy Now. On May 7, Lake Street downgraded LifeVantage Corporation (NASDAQ:LFVN) to Hold from Buy and set a $5 price target after the company reported weaker-than-expected Q3 results. The analyst said management kept its prior FY26 guidance framework in place but now expects […]
Lifevantage Q3 Earnings Call Highlights
Lifevantage (NASDAQ:LFVN) reported fiscal third-quarter 2026 results that reflected a sharp year-over-year revenue decline, as management pointed to weaker demand for its MindBody GLP-1 System and fewer active accounts. On the call, the company also highlighted a leadership transition, ongoing techn
LifeVantage Corporation Q3 2026 Earnings Call Summary
Moby summary of LifeVantage Corporation's Q3 2026 earnings call
Lifevantage (LFVN) Q3 Earnings and Revenues Miss Estimates
Lifevantage (LFVN) delivered earnings and revenue surprises of -25.00% and -8.58%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How A Reset Price Target Is Shaping The Evolving Story For LifeVantage (LFVN)
Analysts have cut their price target on LifeVantage by $7, even as the fair value marker in their updated work holds at $8.0. That shift reflects a reset in expectations that, according to recent commentary, incorporates more caution around earnings power and execution risk while still leaving room for differing views on potential upside. As you read on, you will see how this revised target fits into the evolving analyst story around risk, reward, and what might matter most next for...